文献速递泌尿生殖介入技术与安全PETCTDSA

选择性前列腺动脉与静脉输注PSMA PET/CT放射性配体的药代动力学比较:原发性前列腺腺癌

Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA PET/CT Radioligand Infusions in Primary Prostatic Adenocarcinoma.
PubMed 文献 · Radiology · 2024-01-01

这项前瞻性个体内比较研究纳入5例未治疗的高危前列腺癌男性,分别接受静脉和选择性前列腺动脉输注68Ga-PSMA-11后行动态PET/CT,比较肿瘤感兴趣区的摄取。动脉输注组的SUVmax和SUVmean均高于静脉组,结论认为选择性前列腺动脉输注可提高肿瘤摄取,并认为值得进一步研究PSMA靶向诊疗剂的局部区域动脉内给药。

要点

  • 动脉输注组肿瘤VOI的SUVmax均值938(范围460-1436),静脉组为14(范围3-43),P=0.008。
  • 动脉输注组SUVmean曲线下面积均值14600 SUV×min(范围8353-20025),静脉组为240 SUV×min(范围69-622),P=0.002。
  • 动脉输注组SUVmean在峰值和最终时间点分别比静脉组高46倍和19倍,总体P<0.001。

核心结论

  • 选择性前列腺动脉输注68Ga-PSMA-11后肿瘤SUV高于静脉输注,作者认为值得在高危前列腺癌中进一步研究PSMA靶向诊疗剂的局部区域动脉内给药。

研究设计与样本

  • 前瞻性个体内比较研究,在学术医疗中心纳入5例年龄分别为58、61、64、66、68岁的未治疗前列腺癌男性,于2022年1月至2023年2月入组,间隔1周行两次动态68Ga-PSMA-11 PET/CT,第一次静脉给药,第二次经血管造影置入微导管向前列腺右或左动脉给药。

诊断标准与关键数值

  • 主要结局为前列腺肿瘤VOI的SUVmax,静脉组均值14(范围3-43),动脉组均值938(范围460-1436),P=0.008;次要结局包括SUVmean和SUVmean曲线下面积,动脉组SUVmean总体高于静脉组(P<0.001),峰值和最终时间点分别高46倍和19倍,动脉组AUC均值14600 SUV×min(范围8353-20025),静脉组240 SUV×min(范围69-622),P=0.002。

临床应用与阅片要点

  • 作者认为值得在高危前列腺癌中进一步研究PSMA靶向诊疗剂的局部区域动脉内给药(原文结论)。

局限性

  • 原文结论指出需要进一步研究局部区域动脉内递送PSMA靶向诊疗剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Intravenous prostate-specific membrane antigen (PSMA)-targeted radioligand therapy improves survival in men with metastatic castration-resistant prostate cancer. Yet, the impact of selective prostatic arterial administration on primary tumor uptake is unclear. Purpose To compare gallium 68 (68Ga)-PSMA-11 uptake using dynamic PET/CT in prostatic tumoral volumes of interest (VOIs) during intravenous and selective prostatic arterial infusions for individuals with untreated, high-risk prostate cancer. Materials and Methods In this prospective, intraindividual comparative study conducted at an academic medical center, five men aged 58, 61, 64, 66, and 68 years with treatment-naive prostate cancer were enrolled between January 2022 and February 2023 and underwent two dynamic 68Ga-PSMA-11 PET/CT examinations 1 week apart. During the first examination, the radiotracer was administered intravenously. During the second administration, the radiotracer was delivered into either the right or left prostatic artery through an angiographically placed microcatheter. The primary outcome was maximum standardized uptake value (SUVmax) in prostatic tumoral VOIs. The secondary outcomes included mean SUV (SUVmean) in prostatic tumoral VOIs and area under the SUVmean curves (AUC). Longitudinal mixed-effects models were used to compare dynamic SUVmax and SUVmean time-activity curves (TACs), and paired t tests were used for the remaining data. Results The mean SUVmax within tumoral VOIs was 14 (range, 3-43) for venous sessions and 938 (range, 460-1436) for arterial sessions (P = .008). The SUVmean within VOIs was greater during arterial sessions (P < .001) overall and 46-fold and 19-fold greater at peak uptake and final time points, respectively. The mean AUC was greater on arterial TACs than on venous TACs at 14600 SUV × min (range, 8353-20025 SUV × min) and 240 SUV × min (range, 69-622 SUV × min), respectively (P = .002). Conclusion Selective prostatic arterial infusion resulted in greater 68Ga-PSMA-11 tumoral SUV than intravenous infusion. Further study of local-regional, intra-arterial delivery of a PSMA-targeted theranostic agent is warranted in high-risk prostate cancer. ClinicalTrials.gov identifier: NCT04976257 © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Civelek in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Kohlbrenner R, Wu X, Nguyen HG, et al. Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA PET/CT Radioligand Infusions in Primary Prostatic Adenocarcinoma. Radiology. 2024. PMID: 39136560. doi:10.1148/radiol.232544

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。